European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

H Ludwig; H Avet-Loiseau; J Blade; M Boccadoro; J Cavenagh; M Cavo; F Davies; J de la Rubia; S Delimpasi; M Dimopoulos; J Drach; H Einsele; T Facon; H Goldschmidt; U Hess; UH Mellqvist; P Moreau; J San-Miguel; P Sondergeld; Pieter Sonneveld; M Udvardy; A Palumbo

doi:10.1634/theoncologist.2011-0391

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

H Ludwig, H Avet-Loiseau, J Blade, M Boccadoro, J Cavenagh, M Cavo, F Davies, J de la Rubia, S Delimpasi, M Dimopoulos, J Drach, H Einsele, T Facon, H Goldschmidt, U Hess, UH Mellqvist, P Moreau, J San-Miguel, P Sondergeld, Pieter SonneveldM Udvardy, A Palumbo

Hematology

Research output: Contribution to journal › Article › Academic

57 Citations (Scopus)

Abstract

The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. The Oncologist 2012;17:592-606

Original language	Undefined/Unknown
Pages (from-to)	592-606
Number of pages	15
Journal	Oncologist
Volume	17
Issue number	5
DOIs	https://doi.org/10.1634/theoncologist.2011-0391
Publication status	Published - 2012

Access to Document

10.1634/theoncologist.2011-0391

http://hdl.handle.net/1765/75170

Cite this

Ludwig, H., Avet-Loiseau, H., Blade, J., Boccadoro, M., Cavenagh, J., Cavo, M., Davies, F., de la Rubia, J., Delimpasi, S., Dimopoulos, M., Drach, J., Einsele, H., Facon, T., Goldschmidt, H., Hess, U., Mellqvist, UH., Moreau, P., San-Miguel, J., Sondergeld, P., ... Palumbo, A. (2012). European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. Oncologist, 17(5), 592-606. https://doi.org/10.1634/theoncologist.2011-0391

@article{f3c3122380104ade89caaf2abba73872,

title = "European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses",

abstract = "The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. The Oncologist 2012;17:592-606",

author = "H Ludwig and H Avet-Loiseau and J Blade and M Boccadoro and J Cavenagh and M Cavo and F Davies and {de la Rubia}, J and S Delimpasi and M Dimopoulos and J Drach and H Einsele and T Facon and H Goldschmidt and U Hess and UH Mellqvist and P Moreau and J San-Miguel and P Sondergeld and Pieter Sonneveld and M Udvardy and A Palumbo",

year = "2012",

doi = "10.1634/theoncologist.2011-0391",

language = "Undefined/Unknown",

volume = "17",

pages = "592--606",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "5",

}

Ludwig, H, Avet-Loiseau, H, Blade, J, Boccadoro, M, Cavenagh, J, Cavo, M, Davies, F, de la Rubia, J, Delimpasi, S, Dimopoulos, M, Drach, J, Einsele, H, Facon, T, Goldschmidt, H, Hess, U, Mellqvist, UH, Moreau, P, San-Miguel, J, Sondergeld, P, Sonneveld, P, Udvardy, M & Palumbo, A 2012, 'European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses', Oncologist, vol. 17, no. 5, pp. 592-606. https://doi.org/10.1634/theoncologist.2011-0391

TY - JOUR

T1 - European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

AU - Ludwig, H

AU - Avet-Loiseau, H

AU - Blade, J

AU - Boccadoro, M

AU - Cavenagh, J

AU - Cavo, M

AU - Davies, F

AU - de la Rubia, J

AU - Delimpasi, S

AU - Dimopoulos, M

AU - Drach, J

AU - Einsele, H

AU - Facon, T

AU - Goldschmidt, H

AU - Hess, U

AU - Mellqvist, UH

AU - Moreau, P

AU - San-Miguel, J

AU - Sondergeld, P

AU - Sonneveld, Pieter

AU - Udvardy, M

AU - Palumbo, A

PY - 2012

Y1 - 2012

N2 - The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. The Oncologist 2012;17:592-606

AB - The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. The Oncologist 2012;17:592-606

U2 - 10.1634/theoncologist.2011-0391

DO - 10.1634/theoncologist.2011-0391

M3 - Article

SN - 1083-7159

VL - 17

SP - 592

EP - 606

JO - Oncologist

JF - Oncologist

IS - 5

ER -